Recent Press Releases

Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals

Merkerson Visits Dallas, Texas on August 14 With America's Diabetes Challenge: Get to Your Goals Program

WHITEHOUSE STATION, N.J.,

Advisory Committee on Immunization Practices Votes to Recommend Pfizer's Prevnar 13® Vaccine in Adults Aged 65 Years and Older

Wednesday, August 13, 2014 - 5:42pm EDT Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP)...

Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical...

Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults

Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults WHITEHOUSE STATION, N.J., Aug 13, 2014...

Foster announces 348 new jobs and £54m investment by Almac Group

Foster announces 348 new jobs and £54m investment by Almac Group Enterprise, Trade and Investment Minister Arlene Foster has announced that the Almac Group is investing over £54 million...

Celltrion files for US FDA approval of Remsima

Celltrion files for US FDA approval of Remsima Remsima® is expected to be the first biosimilar monoclonal antibody to be filed through United States of America Food and Drug Administration's...

Verizon Helps Kids Be Kids at Diabetes Summer Camp

Company's Network and Technology Enable Trial of Artificial Pancreas in California

NEW YORK, Aug.

Access to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage Determination

- Medicare will Provide National Coverage for People with Severe Degenerative Mitral Regurgitation Deemed Too Sick for Surgery

ABBOTT PARK, Ill.,

Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection)

BRIDGEWATER, N.J., Aug. 12, 2014 /PRNewswire/ -- Sanofi US announced today that it has launched an authorized generic version of Eloxatin® (oxaliplatin injection) through Winthrop US, the...

Synta Reports Second Quarter Financial Results and Provides Corporate Update

Synta Reports Second Quarter Financial Results and Provides Corporate Update Webcast and Conference Call Today, August 6, at 10:00 AM ET LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- Synta...

Synta Names Anne Whitaker Chief Executive Officer

Synta Names Anne Whitaker Chief Executive Officer LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Anne Whitaker will join the Company...

FDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug...

First half year 2014: Boehringer Ingelheim meets challenges

Net sales of around €6.5 billion achieved in the first half year Preparations for additional product launches in full swing Initiative to improve cost structure launched Ingelheim,...

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME) TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN...

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 7% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 7% in...

Regeneron Reports Second Quarter 2014 Financial and Operating Results

- Second quarter 2014 EYLEA® (aflibercept) Injection global net sales increased 53% to $662 million (consisting of $415 million in the U.S. and $247 million in rest of world(1)) versus second...